68Ga-NOTA-BBN-RGD PET/CT in Prostate Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02747290|
Recruitment Status : Unknown
Verified March 2016 by gwcmc.
Recruitment status was: Recruiting
First Posted : April 21, 2016
Last Update Posted : April 21, 2016
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: 68Ga-NOTA-BBN-RGD||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety and Diagnostic Performance of 68Gallium-labeled NOTA-BBN-RGD PET/CT in Prostate Cancer Patients|
|Study Start Date :||July 2014|
|Estimated Primary Completion Date :||July 2017|
Experimental: 68Ga-NOTA-BBN-RGD PET/CT
The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
- Standardized uptake value of 68Ga-NOTA-BBN-RGD in prostate cancer [ Time Frame: 1 year ]The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (SUV) of the tracer in prostate cancer will be measured.
- Adverse events collection [ Time Frame: 1 week ]Adverse events within 1 week after the injection and scanning of patients and patients will be followed and assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02747290
|Contact: Zhaohui Zhu, MD.PhD.||+86 10 firstname.lastname@example.org|
|Contact: Jingjing Zhang, MD.PhD.||+86 10 email@example.com|
|Peking Union Medical College Hospital||Recruiting|
|Beijing, Beijing, China, 100730|
|Contact: Jingjing Zhang, MD. +86 10 69155513 firstname.lastname@example.org|
|Study Chair:||Fang Li, MD.||Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College|